Lineage Cell Therapeutics annual depreciation and amortization
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Lineage Cell Therapeutics Depreciation & Amortization Growth & History (LCTX)
Lineage Cell Therapeutics's depreciation and amortization was $699,000 for fiscal 2025.
View full Lineage Cell Therapeutics company overviewLineage Cell Therapeutics annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $699,000 | $112,000 | +19.08% |
| 2024 | 2024-12-31 | $587,000 | $25,000 | +4.45% |
| 2023 | 2023-12-31 | $562,000 | −$20,000 | −3.44% |
| 2022 | 2022-12-31 | $582,000 | −$81,000 | −12.22% |
| 2021 | 2021-12-31 | $663,000 | −$160,000 | −19.44% |
| 2020 | 2020-12-31 | $823,000 | −$179,000 | −17.86% |
| 2019 | 2019-12-31 | $1.0M | −$79,000 | −7.31% |
| 2018 | 2018-12-31 | $1.1M | $134,000 | +14.15% |
| 2017 | 2017-12-31 | $947,000 | −$233,000 | −19.75% |
| 2016 | 2016-12-31 | $1.2M | $102,000 | +9.46% |
| 2015 | 2015-12-31 | $1.1M | $27,000 | +2.57% |
| 2014 | 2014-12-31 | $1.1M | −$2.9M | −73.41% |
| 2013 | 2013-12-31 | $4.0M | $1.1M | +39.51% |
| 2012 | 2012-12-31 | $2.8M | $468,883 | +19.83% |
| 2011 | 2011-12-31 | $2.4M | $1.4M | +154.59% |
| 2010 | 2010-12-31 | $928,776 | $894,185 | +2585.02% |
| 2009 | 2009-12-31 | $34,591 | — | — |
Lineage Cell Therapeutics quarterly depreciation and amortization
Q3.10
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $187,000 | $16,000 | +9.36% |
| Q1 2026 | 2026-03-31 | $188,000 | $24,000 | +14.63% |
| Q4 2025 | 2025-12-31 | $186,000 | — | — |
| Q3 2025 | 2025-09-30 | $178,000 | $37,000 | +26.24% |
| Q2 2025 | 2025-06-30 | $171,000 | $29,000 | +20.42% |
| Q1 2025 | 2025-03-31 | $164,000 | $11,000 | +7.19% |
| Q3 2024 | 2024-09-30 | $141,000 | −$142.9M | −99.90% |
| Q2 2024 | 2024-06-30 | $142,000 | −$137.9M | −99.90% |
| Q1 2024 | 2024-03-31 | $153,000 | $15,000 | +10.87% |
| Q3 2023 | 2023-09-30 | $143.0M | −$2.0M | −1.38% |
| Q2 2023 | 2023-06-30 | $138.0M | −$8.0M | −5.48% |
| Q1 2023 | 2023-03-31 | $138,000 | −$12,000 | −8.00% |
| Q3 2022 | 2022-09-30 | $145.0M | $144.8M | +87778.79% |
| Q2 2022 | 2022-06-30 | $146.0M | $145.8M | +88384.85% |
| Q1 2022 | 2022-03-31 | $150,000 | −$24,000 | −13.79% |
| Q3 2021 | 2021-09-30 | $165,000 | −$35,000 | −17.50% |
| Q2 2021 | 2021-06-30 | $165,000 | −$45,000 | −21.43% |
| Q1 2021 | 2021-03-31 | $174,000 | −$38,000 | −17.92% |
| Q3 2020 | 2020-09-30 | $200,000 | −$53,000 | −20.95% |
| Q2 2020 | 2020-06-30 | $210,000 | −$34,000 | −13.93% |
| Q1 2020 | 2020-03-31 | $212,000 | −$57,000 | −21.19% |
| Q3 2019 | 2019-09-30 | $253,000 | −$1,000 | −0.39% |
| Q2 2019 | 2019-06-30 | $244,000 | −$35,000 | −12.54% |
| Q1 2019 | 2019-03-31 | $269,000 | −$12,000 | −4.27% |
| Q3 2018 | 2018-09-30 | $254,000 | $5,000 | +2.01% |
| Q2 2018 | 2018-06-30 | $279,000 | $74,000 | +36.10% |
| Q1 2018 | 2018-03-31 | $281,000 | $65,000 | +30.09% |
| Q3 2017 | 2017-09-30 | $249,000 | $1,000 | +0.40% |
| Q2 2017 | 2017-06-30 | $205,000 | −$114,000 | −35.74% |
| Q1 2017 | 2017-03-31 | $216,000 | −$213,000 | −49.65% |
| Q3 2016 | 2016-09-30 | $248,000 | −$1.3M | −84.28% |
| Q2 2016 | 2016-06-30 | $319,000 | −$1.2M | −79.59% |
| Q1 2016 | 2016-03-31 | $429,000 | −$1.1M | −72.80% |
| Q3 2015 | 2015-09-30 | $1.6M | −$61,000 | −3.72% |
| Q2 2015 | 2015-06-30 | $1.6M | −$71,057 | −4.35% |
| Q1 2015 | 2015-03-31 | $1.6M | −$47,943 | −2.95% |
| Q3 2014 | 2014-09-30 | $1.6M | $576,797 | +54.30% |
| Q2 2014 | 2014-06-30 | $1.6M | $878,129 | +116.17% |
| Q1 2014 | 2014-03-31 | $1.6M | $869,014 | +114.96% |
| Q3 2013 | 2013-09-30 | $1.1M | $321,596 | +43.42% |
| Q2 2013 | 2013-06-30 | $755,928 | $79,542 | +11.76% |
| Q1 2013 | 2013-03-31 | $755,929 | $131,500 | +21.06% |
| Q3 2012 | 2012-09-30 | $740,607 | $23,220 | +3.24% |
| Q2 2012 | 2012-06-30 | $676,386 | $28,047 | +4.33% |
| Q1 2012 | 2012-03-31 | $624,429 | $103,033 | +19.76% |
| Q3 2011 | 2011-09-30 | $717,387 | $492,215 | +218.60% |
| Q2 2011 | 2011-06-30 | $648,339 | — | — |
| Q1 2011 | 2011-03-31 | $521,396 | — | — |
| Q3 2010 | 2010-09-30 | $225,172 | — | — |
Lineage Cell Therapeutics depreciation and amortization trends
Over the last five fiscal years, Lineage Cell Therapeutics's depreciation and amortization decreased from $823,000 to $699,000, a change of −$124,000. The latest reported quarter, Q2 2026, shows $187,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Lineage Cell Therapeutics source filings ↗